Inspirna Raises $50M in Series D Financing
Summary
Led by CEO Masoud Tavazoie, Inspirna is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Its lead drug candidate, RGX-202-01, is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. RGX-202-01 is currently being tested in a Phase 1b clinical trial in combination with standard-of-care FOLFIRI and bevacizumab for the second line treatment of patients with advanced or metastatic CRC. In addition, the company is advancing RGX-104, an oral small molecule activator of LXR/APOE that inhibits angiogenesis and tumor myeloid derived suppressor cells to enhance the immune response against tumors. The company intends to use the funds to support the clinical development of RGX-202-01 and RGX-104.